ClinicalTrials.gg
Active, not recruitingNCT06861439GLOWUpdated Oct 2, 2026

GLP-1s to Enhance Lasting Optimal Weight

A Phase 4 interventional study of Tirzepatide in Obesity, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 2, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies testing tirzepatide in Obesity — 62 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
74th of 106
40 · median 69
Started
2025
with 33 others
Phase 4
30 of 106
21 open now
Primary completion
2027-10
later than 38 of 78 live
Registered
43rd of 106
by date

Among the 106 studies testing tirzepatide in Obesity, this one is the 74th largest by enrollment, is one of 34 that started in 2025, is one of 30 in phase 4, reaches primary completion later than 38 of the 78 other live ones, and was the 43rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

62 of the 106 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

57 more — sign in →

By country, each count listing its studies:

All 62 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in person or video conference, attend group intervention sessions twice a month via video conference, weigh daily with a study-provided smart scale, keep a record of all foods and beverages consumed, and use a study-provided activity tracker to keep track of daily step counts.

Read the detailed description

This study will enroll 40 older adults with obesity (or overweight with a weight-related comorbidity) in a 9-month pilot to examine the effects of tirzepatide on body composition, bone health, and physical performance. All participants will receive tirzepatide, 5 mg per week and counseling sessions (group and individual) on diet quality and physical activity as well as behavioral strategies to facilitate dietary and physical activity changes. Participants will be expected to weigh themselves daily on a smart scale, record their food and beverage consumption, and keep track of daily step counts over the 9-month intervention period. Body composition, bone health, and physical performance will be measured at baseline prior to intervention and approximately nine months later. This data will be used to examine the effects of tirzepatide on total and appendicular lean and total fat mass measured by DXA; hip and spine bone mineral density measured by DXA; and leg strength and physical performance (expanded Short Physical Performance Battery, 400-m walk).

03

Conditions studied

  • Obesity

Keywords

  • Weight Loss
  • Muscle Loss
  • Physical Disability
  • Bone Density
  • Older Adults
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30-37 kg/m2 or BMI 27-\<30 kg/m2 with at least 1 weight-related comorbidity
  • community dwelling
  • able to provide own transportation to study visits
  • willing to provide
  • willing to take terzepatide for 9 months
  • agree to all study procedures/assessments
  • approved for participation by the study physician

Exclusion criteria

Exclusion Criteria:

  • dependent on a cane or walker or needing assistance with any activity of daily living
  • history of mild cognitive impairment or dementia or cognitive impairment on (MoCA score \<22)
  • evidence of depressive symptoms (Center for Epidemiologic Studies Depression scale score =>16
  • use of >1 tobacco product/day or 4/week or vaped >1/week in past year
  • excessive alcohol use in past month (>7 drinks/week for women; >14 drinks/week for men)
  • weight loss or gain >5% in past 3 months
  • vegan or other severe dietary restriction
  • history of binge eating disorder
  • regular participation in high intensity aerobic or resistance exercise training >150 mins/week
  • severe arthritis, fracture, chronic injury, or other musculoskeletal disorder that prevents walking independently
  • joint replacement or other orthopedic surgery in past 6 months or planned in next 12 months
  • osteoporosis (self report or DXA t-score \<= -2.5 on total hip and/or femoral neck)
  • uncontrolled hypertension (systolic >160 OR diastolic >100 mmHg) upon repeated assessments
  • type 1 diabetes
  • uncontrolled type 2 diabetes ( >7.5%), type 2 diabetes diagnosed within last year, or newly identified type 2 diabetes (HbA1c >6.5%)
  • dialysis or abnormal kidney function ( \<30 ml/min/1.73m2)
  • liver disease or abnormal liver function ( levels 2 times above normal limit)
  • severe anemia ( \<11 g/dL)
  • potassium or sodium above or below normal limits
  • uncontrolled thyroid disease (hypo/hyper) or requiring recent (past 3 months) adjustments in thyroid hormone supplementation or TSH \<0.45 or >4.5 mU/L
  • stroke, heart attack, heart failure hospitalization, or revascularization procedure within the past year; New York heart failure Class >2; requiring oxygen use; uncontrolled angina; PAD diagnosis within the last year; progressive neurologic disease (e.g., Parkinson's, ALS, MS); other diseases suggesting a life-expectancy \<3 years
  • personal or family history of medullary thyroid carcinoma, history of multiple endocrine neoplasia syndrome type 2, or any other cancer (except non-melanoma skin cancers) requiring treatment in past year
  • history of gastroparesis or pancreatitis
  • cholelithiasis, severe irritable bowel syndrome or Crohn's disease
  • history of stomach or small intestinal surgery (except appendectomy but including surgery for weight loss)
  • recent (within 4 weeks) acute respiratory illness including influenza, COVID-19
  • overnight hospitalization within the past 6 months
  • regular use of growth hormones, medications prescribed for weight management, prescription osteoporosis medications, certain prescription medications for diabetes including insulin, sulfonylurea, meglitinides, GLP-1 agonists, SGLT2 inhibitors
  • use of oral for >1 month within the last 3 months
  • current participation in another intervention research study
  • planned out of town trips greater than 3 weeks in the next year
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Tirzepatide injection once weekly for 9 months

    Drug: Tirzepatide

Interventions

  • Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.

    Also known as: Zepbound

06

What researchers measure

Primary outcomes

  1. Change in total body lean mass

    Change in total body lean mass will be measured by DXA scan

    Time frame: Baseline to Month 9

  2. Change in total body lean mass

    Change in total body lean mass will be measured by DXA scan

    Time frame: Month 9 to Month 21

  3. Change in appendicular lean mass

    Change in appendicular lean mass will be measured by DXA scan

    Time frame: Baseline to Month 9

  4. Change in appendicular lean mass

    Change in appendicular lean mass will be measured by DXA scan

    Time frame: Month 9 to Month 21

  5. Change in total body fat mass

    Change in total body fat mass will be measured by DXA scan

    Time frame: Baseline to Month 9

  6. Change in total body fat mass

    Change in total body fat mass will be measured by DXA scan

    Time frame: Month 9 to Month 21

  7. Change in total hip bone mineral density

    Change in total hip bone mineral density will be measured by DXA scan

    Time frame: Baseline to Month 9

  8. Change in total hip bone mineral density

    Change in total hip bone mineral density will be measured by DXA scan

    Time frame: Month 9 to Month 21

  9. Change in lumbar spine bone mineral density

    Change in lumbar spine bone mineral density will be measured by DXA scan

    Time frame: Baseline to Month 9

  10. Change in lumbar spine bone mineral density

    Change in lumbar spine bone mineral density will be measured by DXA scan

    Time frame: Month 9 to Month 21

  11. Change in 400 meter walk time

    Change in the time it takes to walk 400 meters (10 laps on an indoor, 20-meter course). The 400 meter walk is a test of exercise tolerance and aerobic fitness.

    Time frame: Baseline to Month 9

  12. Change in 400 meter walk time

    Change in the time it takes to walk 400 meters (10 laps on an indoor, 20-meter course). The 400 meter walk is a test of exercise tolerance and aerobic fitness.

    Time frame: Month 9 to Month 21

  13. Change in lower extremity physical performance score

    Change in lower extremity physical performance will be assessed by the expanded Short Physical Performance Battery. Activities include side-by-side, semi-tandem, tandem and one leg stand balance tests; 4 meter walk; 4 meter narrow walk; and time to rise from a chair five times. Total score ranges from 0-4 with higher scores indicating better lower extremity physical performance.

    Time frame: Baseline to Month 9

  14. Change in lower extremity physical performance score

    Change in lower extremity physical performance will be assessed by the expanded Short Physical Performance Battery. Activities include side-by-side, semi-tandem, tandem and one leg stand balance tests; 4 meter walk; 4 meter narrow walk; and time to rise from a chair five times. Total score ranges from 0-4 with higher scores indicating better lower extremity physical performance.

    Time frame: Month 9 to Month 21

  15. Change in leg strength

    Change in leg extensor strength will be assessed using the Keiser AIR300 Leg Press System.

    Time frame: Baseline to Month 9

  16. Change in grip strength

    Change in grip strength will be assessed using the Jamar hand-held dynamometer

    Time frame: Baseline to Month 9

  17. Change in grip strength

    Change in grip strength will be assessed using the Jamar hand-held dynamometer

    Time frame: Month 9 to Month 21

  18. Change in leg strength

    Change in leg extensor strength will be assessed using the Keiser AIR300 Leg Press System.

    Time frame: Month 9 to Month 21

Secondary outcomes

  1. Change in thigh intramuscular fat tissue

    Change in thigh intramuscular fat tissue will be measured by CT scan

    Time frame: Baseline to Month 9

  2. Change in thigh muscle volume

    Change in thigh muscle volume will be measured by CT scan

    Time frame: Baseline to Month 9

  3. Change in total skeletal muscle mass

    Change in total skeletal muscle mass will be assessed by D3 creatine

    Time frame: Baseline to Month 9

  4. Change in total volumetric bone mineral density of the hip

    Change in total volumetric bone mineral density of the hip will be measured by CT scan

    Time frame: Baseline to Month 9

  5. Change in hip bone strength

    Change in hip bone strength will be measured by CT scan

    Time frame: Baseline to Month 9

  6. Change in total volumetric bone mineral density of the radius

    Change in total volumetric bone mineral density of the radius will be measured by high-resolution peripheral quantitative CT

    Time frame: Baseline to Month 9

  7. Change in total volumetric bone mineral density of the tibia

    Change in total volumetric bone mineral density of the tibia will be measured by high-resolution peripheral quantitative CT

    Time frame: Baseline to Month 9

  8. Change in c-telopeptide of type 1 collagen (CTX)

    Change in c-telopeptide of type 1 collagen (CTX) will be measured by enzyme-linked immunosorbent assay

    Time frame: Baseline to Month 9

  9. Change in procollagen type 1 n-terminal propeptide (P1NP)

    Change in procollagen type 1 n-terminal propeptide (P1NP) will be measured by enzyme-linked immunosorbent assay

    Time frame: Baseline to Month 9

  10. Change in bone-specific alkaline phosphatase (BALP)

    Change in bone-specific alkaline phosphatase (BALP) will be measured by enzyme-linked immunosorbent assay

    Time frame: Baseline to Month 9

  11. Change in osteocalcin

    Change in osteocalcin will be measured by enzyme-linked immunosorbent assay

    Time frame: Baseline to Month 9

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2027, 27 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 27 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2027, last on Oct 2, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 6, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Oct 30, 2027was Sep 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Oct 30, 2027
moved 2 times, Sep 28, 2026 – Oct 2, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 2, 2026
Primary outcomes
10 added
What changed in the outcomes
  • AddedChange in total body lean massTime frame: Month 9 to Month 21
  • AddedChange in appendicular lean massTime frame: Month 9 to Month 21
  • AddedChange in total body fat massTime frame: Month 9 to Month 21
  • AddedChange in total hip bone mineral densityTime frame: Month 9 to Month 21
  • AddedChange in lumbar spine bone mineral densityTime frame: Month 9 to Month 21
  • AddedChange in 400 meter walk timeTime frame: Month 9 to Month 21
  • AddedChange in lower extremity physical performance scoreTime frame: Month 9 to Month 21
  • AddedChange in grip strengthTime frame: Baseline to Month 9
  • AddedChange in grip strengthTime frame: Month 9 to Month 21
  • AddedChange in leg strengthTime frame: Month 9 to Month 21
Oct 2, 2026
Show all 2 updates
  1. Oct 2, 2026
    Primary completion Oct 30, 2026→Oct 30, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Primary outcomes 10 added
    What changed in the outcomes
    • AddedChange in total body lean massTime frame: Month 9 to Month 21
    • AddedChange in appendicular lean massTime frame: Month 9 to Month 21
    • AddedChange in total body fat massTime frame: Month 9 to Month 21
    • AddedChange in total hip bone mineral densityTime frame: Month 9 to Month 21
    • AddedChange in lumbar spine bone mineral densityTime frame: Month 9 to Month 21
    • AddedChange in 400 meter walk timeTime frame: Month 9 to Month 21
    • AddedChange in lower extremity physical performance scoreTime frame: Month 9 to Month 21
    • AddedChange in grip strengthTime frame: Baseline to Month 9
    • AddedChange in grip strengthTime frame: Month 9 to Month 21
    • AddedChange in leg strengthTime frame: Month 9 to Month 21
  2. Sep 28, 2026
    Primary completion Sep 30, 2026→Oct 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06861439
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Jul 7, 2025
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Denise Houston, PhD
principal investigator · Atrium Health Wake Forest Baptist

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion